CRISPR Therapeutics AG (CRSP) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
CRSP rises 2.6% to $51.52. Closed at $51.52, +2.59% vs the prior close of $50.22. Day range $49.76–$52.37, opened at $50.00.
CRSP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CRSP rises 2.6% to $51.52
- Closed at $51.52, +2.59% vs the prior close of $50.22. Day range $49.76–$52.37, opened at $50.00.
- Volume was 1.35M shares, 0.9x its 50-day average of 1.57M.
- Price is -6.3% vs its 50-day average ($54.99) and -3.0% vs its 200-day average ($53.13).
- 52-week range $44.12–$75.06; today's close sits at 24% of that range, 31.4% below the 52-week high.
Oct 14, 2026 — CRSP ends flat (+0.2%) to $50.22
- Closed at $50.22, +0.24% vs the prior close of $50.10. Day range $48.91–$50.78, opened at $49.67.
- Volume was 1.70M shares, 1.1x its 50-day average of 1.58M.
- Price is -8.7% vs its 50-day average ($55.01) and -5.5% vs its 200-day average ($53.14).
- 52-week range $44.12–$75.06; today's close sits at 20% of that range, 33.1% below the 52-week high.
Oct 13, 2026 — CRSP dips 2.8% to $50.10, a 1-month low
- Closed at $50.10, -2.81% vs the prior close of $51.55. Day range $49.77–$51.11, opened at $51.01.
- Volume was 1.34M shares, 0.8x its 50-day average of 1.58M.
- Price is -9.0% vs its 50-day average ($55.07) and -5.8% vs its 200-day average ($53.17).
- 52-week range $44.12–$75.16; today's close sits at 19% of that range, 33.3% below the 52-week high.
Oct 12, 2026 — CRSP slides 3.4% to $51.55
- Closed at $51.55, -3.45% vs the prior close of $53.39. Day range $51.40–$53.21, opened at $52.91.
- Volume was 1.10M shares, 0.7x its 50-day average of 1.58M.
- Price is -6.4% vs its 50-day average ($55.06) and -3.1% vs its 200-day average ($53.20).
- 52-week range $44.12–$78.00; today's close sits at 22% of that range, 33.9% below the 52-week high.
Oct 9, 2026 — CRSP jumps 5.8% to $53.39
- Closed at $53.39, +5.85% vs the prior close of $50.44. Day range $50.52–$54.07, opened at $50.82.
- Volume was 1.47M shares, 0.9x its 50-day average of 1.58M.
- Price is -2.9% vs its 50-day average ($54.99) and +0.3% vs its 200-day average ($53.23).
- 52-week range $44.12–$78.38; today's close sits at 27% of that range, 31.9% below the 52-week high.
Oct 8, 2026 — CRSP slides 3.6% to $50.44, a 1-month low on 1.8x normal volume
- Closed at $50.44, -3.65% vs the prior close of $52.35. Day range $50.02–$53.54, opened at $51.51.
- Volume was 2.86M shares, 1.8x its 50-day average of 1.56M — unusually heavy trading.
- Price is -8.1% vs its 50-day average ($54.89) and -5.3% vs its 200-day average ($53.25).
- 52-week range $44.12–$78.48; today's close sits at 18% of that range, 35.7% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — CRSP slides 3.1% to $52.35
- Closed at $52.35, -3.06% vs the prior close of $54.00. Day range $52.27–$54.59, opened at $53.00.
- Volume was 1.68M shares, 1.1x its 50-day average of 1.56M.
- Price is -4.5% vs its 50-day average ($54.83) and -1.7% vs its 200-day average ($53.28).
- 52-week range $44.12–$78.48; today's close sits at 24% of that range, 33.3% below the 52-week high.
Oct 6, 2026 — CRSP slides 5.8% to $54.00
- Closed at $54.00, -5.82% vs the prior close of $57.34. Day range $53.74–$60.68, opened at $60.38.
- Volume was 2.62M shares, 1.7x its 50-day average of 1.54M.
- Price is -1.3% vs its 50-day average ($54.73) and +1.3% vs its 200-day average ($53.29).
- 52-week range $44.12–$78.48; today's close sits at 29% of that range, 31.2% below the 52-week high.
Oct 5, 2026 — CRSP jumps 3.4% to $57.34
- Closed at $57.34, +3.45% vs the prior close of $55.43. Day range $54.01–$57.46, opened at $55.21.
- Volume was 1.70M shares, 1.1x its 50-day average of 1.53M.
- Price is +5.0% vs its 50-day average ($54.59) and +7.6% vs its 200-day average ($53.29).
- 52-week range $44.12–$78.48; today's close sits at 38% of that range, 26.9% below the 52-week high.
Oct 2, 2026 — CRSP ends flat (-0.0%) to $55.43
- Closed at $55.43, -0.02% vs the prior close of $55.44. Day range $54.09–$57.58, opened at $56.45.
- Volume was 1.13M shares, 0.7x its 50-day average of 1.54M.
- Price is +1.9% vs its 50-day average ($54.37) and +4.0% vs its 200-day average ($53.29).
- 52-week range $44.12–$78.48; today's close sits at 33% of that range, 29.4% below the 52-week high.
CRSP latest news & SEC filings
Every SEC filing by or about CRSP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 15, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 14, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 8, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 6, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 24, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kasinger James R. sold 10,400 shares at $60.24 (≈$626.50K) on Sep 22, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 3, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $10.18M (prior year $892.00K) (+1041.4% vs Jun 30, 2025)
- Net income: -$91.15M (prior year -$208.55M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.94 (prior year -$2.40) (loss narrowed vs Jun 30, 2025)
Aug 3, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade CRSP
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Feb 12, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.50% (largest 5.8%).
- Liquidity: about 1.71M shares (≈$88.18M) trade per day on average.
- 52-week position: $51.52 vs a range of $44.12–$75.06 (24% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: James R. Kasinger sold 10,400 shares on Sep 22, 2026.
- Latest filings: 10-Q Aug 3, 2026; 8-K Aug 3, 2026; 8-K Jun 4, 2026.
- Share count: 96.69M shares outstanding (Jul 31, 2026), +6.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CRSP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 50.00 | 52.37 | 49.76 | 51.52 | 1.35M |
| Oct 14, 2026 | 49.67 | 50.78 | 48.91 | 50.22 | 1.70M |
| Oct 13, 2026 | 51.01 | 51.11 | 49.77 | 50.10 | 1.34M |
| Oct 12, 2026 | 52.91 | 53.21 | 51.40 | 51.55 | 1.10M |
| Oct 9, 2026 | 50.82 | 54.07 | 50.52 | 53.39 | 1.47M |
| Oct 8, 2026 | 51.51 | 53.54 | 50.02 | 50.44 | 2.86M |
| Oct 7, 2026 | 53.00 | 54.59 | 52.27 | 52.35 | 1.68M |
| Oct 6, 2026 | 60.38 | 60.68 | 53.74 | 54.00 | 2.62M |
| Oct 5, 2026 | 55.21 | 57.46 | 54.01 | 57.34 | 1.70M |
| Oct 2, 2026 | 56.45 | 57.58 | 54.09 | 55.43 | 1.13M |
| Oct 1, 2026 | 55.44 | 56.59 | 54.82 | 55.44 | 1.06M |
| Sep 30, 2026 | 56.55 | 57.11 | 55.28 | 55.32 | 1.17M |
| Sep 29, 2026 | 54.08 | 56.48 | 54.00 | 56.00 | 1.58M |
| Sep 28, 2026 | 53.84 | 55.63 | 52.90 | 54.09 | 1.27M |
| Sep 25, 2026 | 56.14 | 56.39 | 53.92 | 54.23 | 1.01M |
| Sep 24, 2026 | 54.95 | 57.17 | 53.79 | 55.70 | 1.55M |
| Sep 23, 2026 | 59.10 | 59.52 | 54.67 | 55.76 | 2.36M |
| Sep 22, 2026 | 58.73 | 60.72 | 57.64 | 59.03 | 2.08M |
| Sep 21, 2026 | 57.98 | 59.24 | 56.87 | 58.33 | 1.81M |
| Sep 18, 2026 | 58.00 | 59.34 | 55.63 | 56.56 | 3.38M |
About CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in ZUG. State of incorporation: Switzerland. Fiscal year ends December 31. SEC CIK 1674416.
CRSP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ali Behbahani | Director | Sep 21, 2026 |
| Maria Fardis | Director | Jun 9, 2026 |
| Harold Edward Fleming | Director | Jun 9, 2026 |
| Simeon George | Director | Jun 9, 2026 |
| John Greene | Director | Jun 9, 2026 |
| Katherine A High | Director | Jun 9, 2026 |
| Samarth Kulkarni | Chief Executive Officer | Mar 24, 2026 |
| Sandesh Mahatme | Director | Jun 9, 2026 |
| Briggs Morrison | Director | Jun 9, 2026 |
| Christian Rommel | Director | Jun 9, 2026 |
| Douglas A Treco | Director | Jun 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James R. Kasinger | General Counsel and Secretary | Sep 24, 2026 |
| Samarth Kulkarni | Chief Executive Officer | Mar 24, 2026 |
| Naimish Patel | Chief Medical Officer | Jun 2, 2026 |
| Raju Prasad | Chief Financial Officer | Aug 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | James R. Kasinger | Sale | 10,400 | $60.24 |
| Sep 17, 2026 | Ali Behbahani | Sale | 13,679 | $57.09 |
| May 29, 2026 | Naimish Patel | Sale | 3,786 | $55.62 |
| Mar 23, 2026 | Samarth Kulkarni | Sale | 10,020 | $46.78 |
| Mar 23, 2026 | James R. Kasinger | Sale | 3,182 | $46.78 |
| Mar 23, 2026 | Raju Prasad | Sale | 3,708 | $46.78 |
| Mar 16, 2026 | James R. Kasinger | Sale | 3,450 | $48.26 |
| Mar 16, 2026 | Samarth Kulkarni | Sale | 10,349 | $48.26 |
| Mar 16, 2026 | Naimish Patel | Sale | 3,150 | $48.26 |
| Mar 16, 2026 | Raju Prasad | Sale | 5,848 | $48.26 |
| Mar 16, 2026 | Raju Prasad | Sale | 4,021 | $48.26 |
| Mar 11, 2026 | James R. Kasinger | Sale | 2,800 | $52.80 |
| Mar 11, 2026 | Samarth Kulkarni | Sale | 9,798 | $52.80 |
| Feb 19, 2026 | Samarth Kulkarni | Sale | 6,967 | $52.58 |
| Feb 19, 2026 | James R. Kasinger | Sale | 2,112 | $52.58 |
CRSP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $3.51M | $-581.60M | -6.47 | $-345.01M |
| Dec 31, 2024 | $37.31M | $-366.25M | -4.34 | $-142.77M |
| Dec 31, 2023 | $371.21M | $-153.61M | -1.94 | $-260.38M |
| Dec 31, 2022 | $1.20M | $-650.17M | -8.36 | $-495.74M |
| Dec 31, 2021 | $914.96M | $377.66M | 4.70 | $538.97M |
Latest balance sheet: total assets $2.65B, total liabilities $904.22M, cash $291.34M (as of Jun 30, 2026).
CRSP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $49.57 |
| May 4, 2026 | 8-K Item 2.02 (results) | $53.58 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $48.93 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $54.58 |
| Aug 4, 2025 | 8-K Item 2.02 (results) | $59.59 |
| May 6, 2025 | 8-K Item 2.02 (results) | $33.16 |
| Feb 11, 2025 | 8-K Item 2.02 (results) | $39.62 |
| Nov 5, 2024 | 8-K Item 2.02 (results) | $50.36 |
| Aug 5, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 6, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CRSP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.